M&A Deal Summary

Agilent Acquires e-MSion

On March 9, 2023, Agilent acquired life science company e-MSion

Acquisition Highlights
  • This is Agilent’s 5th transaction in the Life Science sector.
  • This is Agilent’s 28th transaction in the United States.
  • This is Agilent’s 1st transaction in Oregon.

M&A Deal Summary
Date 2023-03-09
Target e-MSion
Sector Life Science
Buyer(s) Agilent
Deal Type Add-on Acquisition

Target

e-MSion

Corvallis, Oregon, United States
e-MSion is an early-stage company behind the innovative electron capture dissociation (ECD) technology known as the ExD cell. e-MSion is based in Corvallis, Oregon.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Agilent

Santa Clara, California, United States
Category Company
Founded 1999
Sector Test/Measurement Equipment
Employees17,600
Revenue 6.8B USD (2023)
DESCRIPTION
Entrance to Agilent's headquarters in Santa Clara, California.
Entrance to Agilent's headquarters in Santa Clara, California.

Agilent is a producer of solutions that includes instruments, software, services, and consumables for the entire laboratory workflow. Agilent's life sciences and applied markets business provide application-focused solutions that include instruments and software that enable customers to identify, quantify, and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular level. Agilent was founded in 1999 and is based in Santa Clara, California.

DEAL STATS #
Overall 37 of 38
Sector (Life Science) 5 of 6
Type (Add-on Acquisition) 34 of 35
State (Oregon) 1 of 1
Country (United States) 28 of 28
Year (2023) 2 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2023-01-04 Avida Biomed

Fremont, California, United States

Avida Biomed is an early-stage life sciences company that develops high-performance target enrichment workflows with unique capabilities for clinical researchers utilizing next-generation sequencing (NGS) approaches to study cancer. The company's genomics tools enable simultaneous genomic and DNA methylation profiling from a single sample without compromising sensitivity or specificity. Its technology will enable scientists working in precision medicine to develop new approaches for a variety of applications including biomarker discovery, patient selection for clinical trials, diagnosis and prognosis, therapy selection, and disease recurrence. Avida Biomed is based in Fremont, California.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2024-07-22 BioVectra

Charlottetown, Prince Edward Island, Canada

BioVectra is a provider of contract manufacturing services to the global pharmaceutical and biotechnology industry and manufactures active pharmaceutical ingredients (API's), chemical intermediates, and bioprocessing reagents. BioVectra was founded in 1970 and is based in Charlottetown, Prince Edward Island.

Buy $925M
Mergr

Product

Company

Legal